The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia

Hematology

Volumn 13, Issue 3, 2008, Pages 147-153

  AbdelSalam, Mahmoud ^a,d   El Sissy, A ^b   Samra, M A ^c   Ibahim, S ^b   El Markaby, D ^a   Gadallah, F ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

B CLL SLL; P53 gene; Rb1 gene; Trisomy 12

Indexed keywords

CHLORAMBUCIL; PREDNISONE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME DELETION 13; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EGYPT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; INTERPHASE; KARYOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; METAPHASE; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; TRISOMY 12;

ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 12; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MIDDLE AGED; PROGNOSIS; RETINOBLASTOMA PROTEIN; TRISOMY;

EID: 55849145503     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X316121     Document Type: Article

References (28)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 104-114.
3. Jaffe ES, Harris NL, Stein H, vardiman J. Pathology and genetic of tumors of haemopoietic and lymphoid tissues, 1st ed. Lyon: IARC Press, 2001.
4. Keating MJ, Chiorazzi N, Messmer B et al. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003. American Socoity of Hematology Education Program book, Washington, DC: American Society of Hematology, 2003; 153-175.
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
6. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206
7. Zwiebel JA, Cheson BD: CSronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59.
8. Aoun P, Blair HE, Smith LM et al. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2004; 45: 1595-1603.
9. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
10. Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980; 56: 640-647.
11. Robert KH, Gahrton G, Friberg K, Zech L, Nilsson B. Extra chromosome 12 and prognosis in chronic lymphocytic leukaemia. Scand J Haematol 1982; 28: 163-168.
12. Neilson JR, Auer R, White D et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997; 11: 1929-1932.
13. Juliusson G, Oscier D, Fitchett M. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
14. Dohner h, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
15. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007.
16. Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960; 20: 613-616.
17. Paris Conference (1971), supplement (1975). Standardization in human cytogenetics. Cytogenet Cell Genet 1975; 15: 203-238.
18. An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artic Ser 1985; 21: 1-117.
19. Garcia-Marco JA, Nouel A, Navarro B et al. Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: Frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14. Cancer Res 1998; 58: 1736-1740.
20. Shaw GR, Kronberger DL. TP53 deletions but not trisomy 12 are adverse in B-cell lymphoproliferative disorders. Cancer Genet Cytogenet 2000; 119: 146-154.
21. Dewald GW. Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. Int J Hematol 2002; 76(Suppl 2): 65-74.
22. Dewald GW, Brockman SR, Paternoster SF et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: Correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287-295.
23. Oscier DG, Gardiner AC, Mould SJ et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
24. Jarosova M, Jedlickova K, Holzerova M et al. Methods in molecular cytogenetics for determination of prognistically important chromosome changes in patients with chronic lymphatic leukemias. Cas Lek Cesk 2000; 139: 564-569.
25. Byrd JC, Smith L, Hackbarth ML et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36-38.
26. El Rouby S, Thomas A, Costin D et al. p53 gene-mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459.
27. Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
28. Byrd JC, Gribben JG, Peterson BL et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443